Relay Therapeutics

Survey data in #metastaticbreastcancer patients show they are just as concerned about quality of life and side effects of medication as they are about their disease progression. Dr. Sarah Sammons MD, a medical oncologist specializing in the care of patients with breast cancer at Dana-Farber and a primary investigator for Relay Tx’s ReDiscover trial, joined the Susan G. Komen Real Pink podcast to discuss the potential of personalized medicine in metastatic breast cancer. 

Our Director of Biology, Fabien Llambi, will present our differentiated preclinical work in #vascularmalformations at #VAC2025 this week. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. This marks a significant milestone in our journey to develop transformative therapies for patients. Congratulations to Fabien and our entire vascular malformations team on this achievement! 🎉

Eight was great, but nine is divine! Today, we celebrate nine years of innovation, dedication, and impact. A huge thank you to our incredible team of Relayers and the patients, families, and investigators who inspire our mission every day. Here’s to the past, the future, and the lives we strive to change - cheers to 9! 🎂

Relay Therapeutics CEO Sanjiv Patel will present at #JPM25 on what's to come this year as we continue to transform the #drugdiscovery landscape. Find more details below. We look forward to connecting in San Francisco!

𝘛𝘪𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺 🎁 This holiday season, Relayers partnered with Happy Hope Factory to assemble activity-filled bundles for children at our local Boston-area hospitals. Each bundle included games related to STEM and the arts, and hopefully lots of 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺, 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺.

Today, we announced updated data for RLY-2608 + fulvestrant that continue to demonstrate clinically meaningful progression free survival, which will be shared at #SABCS24 today. President of R&D Dr. Donald Bergstrom shares more about the significance of these data below. Tune into our conference call this morning, December 11, at 7:00AM ET for more insight. Learn more here. https://lnkd.in/erSDuRDJ

We are pleased to announce we will present updated clinical data for RLY-2608 + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic #breastcancer at #SABCS24. We will host a conference call to discuss these data on Wednesday, December 11 at 7:00 a.m. ET. Find more details here. https://lnkd.in/eAH-dQTG

Today, we're pleased to announce we have entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib, a highly selective irreversible small-molecule inhibitor of FGFR2, in FGFR2-driven cholangiocarcinoma and other solid tumors. Learn more here. https://lnkd.in/eJ7rfS75

At Relay Tx, we always gather for lunch.   You grab a seat at any table with any colleague from any group.   🦃 Yesterday’s Thanksgiving lunch looked like any other day of the week - with extra gratitude and extra gravy.

Key takeaways from our lunch with Relay Tx board member Jami Rubin: ✨ Seek out your mentors; they won’t find you ✨ Professional confidence takes time: you need to put in the hours and the reps ✨ Operate from a place of fearlessness   A big thank you to COO Imogen Pryce and our employee resource group, EmpowHER, for organizing an inspiring chat show!